title: Novel combination regimens: biologics and acitretin for the treatment of psoriasis-- a case series.
abstract: Combination therapy has long been a mainstay of psoriasis treatment, particularly for those that suffer from moderate-to-severe disease. The biologics represent a new and exciting approach to psoriasis treatment though their use in combination regimens has not been adequately examined. This brief series reports on the combination of biologics with acitretin in the treatment of psoriasis.
authors.affiliation: Department of Dermatology, Center for Dermatology Research, Wake Forest University School of Medicine, Winston-Salem, NC 27157-1071, USA.
authors.forename: Jared
authors.initials: J
authors.lastname: Conley
authors.forename: Jaleema
authors.initials: J
authors.lastname: Nanton
authors.forename: Sunil
authors.initials: S
authors.lastname: Dhawan
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Pearce
authors.forename: Steven R
authors.initials: SR
authors.lastname: Feldman
mesh_terms: D017255:Acitretin / Q000008:administration & dosage*; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage*; D007155:Immunologic Factors / Q000008:administration & dosage*; D007641:Keratolytic Agents / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage*; D012720:Severity of Illness Index
chemical_list: D007074:Immunoglobulin G; D007155:Immunologic Factors; D007641:Keratolytic Agents; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins; D017255:Acitretin; D000068800:Etanercept